BioSpace News Archive

Sales of $222.6 million increased 9.0% as reported and 7.9% in constant currency as compared to the fourth quarter of 2016.

CHOP Oncologists Update Analysis in Pivotal Global Trial of CAR T-Cell Treatment for Relapsed or Refractory ALL [31-January-2018] PHILADELPHIA, Jan. 31, 2018 /PRNewswire-USNewswire/ -- Updated results from a global clinical trial of the CAR T-cell therapy, tisagenlecleucel, a landmark personalized treatment for a high-risk form of acute lymphoblastic leukemia

Owens & Minor expects that net income per diluted share will be in a range $1.17 to $1.20 for the year ended December 31, 2017.

Centric Medical announced today that it will be participating in the 2018 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting which will be held March 6-10 in New Orleans, Louisiana, as well as the 76th Annual 2018 American College of Foot and Ankle Surgeons (ACFAS) Meeting to be held March 22-25 in Nashville, Tennessee.

The innovative NVMF lens design allows it to be used for both myopic progression control and presbyopia.

Tislelizumab is also being studied in global Phase 3 trials in non-small cell lung cancer and hepatocellular carcinoma and two pivotal Phase 2 trials in China in relapsed/refractory classical Hodgkin lymphoma and urothelial cancer.

Lise-Lotte Hallbäck will leave her position as CFO of Immunicum as of today to pursue other interests.

Prof. Blay brings significant experience to the Innate Pharma Supervisory Board.

The v2640 features very high dynamic range and the lowest noise floor of any Phantom camera.

RBC has retained their senior scientist personnel with decades of electrophysiology experience and has begun providing services.